Clinical Trial Update: A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL) [Phase 2]

View source ↗

Summary

Phase 2 trial comparing lenalidomide to investigator's choice in relapsed or refractory mantle cell lymphoma has completed; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Mantle Cell Lymphoma

Drugs mentioned

• Lenalidomide (lenalidomide)

Snippet

Sponsor: Celgene | Conditions: Mantle Cell Lymphoma, Lymphoma, Mantle-Cell | Phase 2 | Status: COMPLETED | Results posted: 2019-09-16